Metformin suppresses Oxidative Stress induced by High Glucose via Activation of the Nrf2/HO-1 Signaling Pathway in Type 2 Diabetic Osteoporosis

被引:39
作者
Chen, Bohao [1 ,2 ]
He, Qi [1 ,2 ]
Yang, Junzheng [1 ,2 ]
Pan, Zhaofeng [1 ,2 ]
Xiao, Jiacong [1 ,2 ]
Chen, Weijian [2 ,3 ]
Chi, Weijin [1 ,2 ]
Li, Miao [1 ,2 ]
Li, Shaocong [1 ,2 ]
Zeng, Jiaxu [1 ,2 ]
Chen, Chuyi [1 ,2 ]
Wang, FanChen [1 ,2 ]
Pang, Xinyuan [4 ]
Yi, Yanzi [5 ]
Tu, Haitao [6 ]
Wang, Haibin [6 ]
Chen, Peng [6 ]
机构
[1] Guangzhou Univ Chinese Med, Sch Med 1, 12 Jichang Rd, Baiyun Area, Guangzhou 510405, Peoples R China
[2] Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Lab Orthopaed & Traumatol, Guangzhou 510405, Peoples R China
[3] Guangzhou Univ Chinese Med, Guangdong Tradit Chinese Med Hosp 2, Guangzhou 510405, Peoples R China
[4] First Hosp Jilin Univ, Dept Neurol, Changchun, Peoples R China
[5] Guangzhou Univ Chinese Med, Affiliated Med Coll 3, Guangzhou 510405, Peoples R China
[6] Guangzhou Univ Chinese Med, Dept Orthopaed, Affiliated Hosp 1, 12 Jichang Rd, Baiyun Area, Guangzhou 510405, Peoples R China
基金
中国国家自然科学基金;
关键词
Metformin; Type 2 diabetic osteoporosis; Oxidative stress; Nrf2; HO-1 signaling pathway; BONE; MELLITUS; OXIDANTS; LEPTIN; IMPACT; CELLS; MODEL;
D O I
10.1016/j.lfs.2022.121092
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
100103 [病原生物学]; 100218 [急诊医学];
摘要
Background: Metformin (MET) is widely used as a first-line hypoglycemic agent for the treatment of type 2 diabetes mellitus (T2DM) and was also confirmed to have a therapeutic effect on type 2 diabetic osteoporosis (T2DOP). However, the potential mechanisms of MET in the treatment of T2DOP are unclear.Objective: To clarify the effect of MET in T2DOP and to explore the potential mechanism of MET in the treatment of T2DOP.Methods: In vitro, we used MC3T3-E1 cells to study the effects of MET on osteogenic differentiation and anti -oxidative stress injury in a high glucose (Glucose 25 mM) environment. In vivo, we directly used db/db mice as a T2DOP model and assessed the osteoprotective effects of MET by Micro CT and histological analysis.Results: In vitro, we found that MET increased ALP activity in MC3T3-E1 cells in a high-glucose environment, promoted the formation of bone mineralized nodules, and upregulated the expression of the osteogenesis-related transcription factors RUNX2, Osterix, and COL1A1-related genes. In addition, MET was able to reduce high glucose-induced reactive oxygen species (ROS) production. In studies on the underlying mechanisms, we found that MET activated the Nrf2/HO-1 signaling pathway and alleviated high-glucose-induced oxidative stress injury. In vivo results showed that MET reduced bone loss and bone microarchitecture destruction in db/db mice. Conclusion: Our results suggest that MET can activate the Nrf2/HO-1 signaling pathway to regulate the inhibition of osteogenic differentiation induced by high glucose thereby protecting T2DOP.
引用
收藏
页数:12
相关论文
共 56 条
[1]
Abdelgawad LM, 2021, REP BIOCHEM MOL BIOL, V10, P30, DOI [10.52547/rbmb.10.1.30, 10.52547/rbmb.10.1.30]
[2]
Curcumin augments the cardioprotective effect of metformin in an experimental model of type I diabetes mellitus; Impact of Nrf2/HO-1 and JAK/STAT pathways [J].
Abdelsamia, Eman M. ;
Khaleel, Sahar A. ;
Balah, Amany ;
Baky, Nayira A. Abdel .
BIOMEDICINE & PHARMACOTHERAPY, 2019, 109 :2136-2144
[3]
[Anonymous], 2019, Nucleic Acids Res, V47, pD520
[4]
A critical review of in vitro research methodologies used to study mineralization in human dental pulp cell cultures [J].
Arora, Shelly ;
Cooper, Paul R. ;
Ratnayake, Jithendra T. ;
Friedlander, Lara T. ;
Rizwan, Shakila B. ;
Seo, Benedict ;
Hussaini, Haizal M. .
INTERNATIONAL ENDODONTIC JOURNAL, 2022, 55 :3-13
[5]
Mitochondria, oxidants, and aging [J].
Balaban, RS ;
Nemoto, S ;
Finkel, T .
CELL, 2005, 120 (04) :483-495
[6]
A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients [J].
Borges, J. L. C. ;
Bilezikian, J. P. ;
Jones-Leone, A. R. ;
Acusta, A. P. ;
Ambery, P. D. ;
Nino, A. J. ;
Grosse, M. ;
Fitzpatrick, L. A. ;
Cobitz, A. R. .
DIABETES OBESITY & METABOLISM, 2011, 13 (11) :1036-1046
[7]
Metformin suppresses adipogenesis through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms [J].
Chen, Suet Ching ;
Brooks, Rebecca ;
Houskeeper, Jessica ;
Bremner, Shaun K. ;
Dunlop, Julia ;
Viollet, Benoit ;
Logan, Pamela J. ;
Salt, Ian P. ;
Ahmed, S. Faisal ;
Yarwood, Stephen J. .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2017, 440 (0C) :57-68
[8]
Irbesartan attenuates advanced glycation end products-mediated damage in diabetes-associated osteoporosis through the AGEs/RAGE pathway [J].
Cheng, Yan-Zhen ;
Yang, Shuang-Li ;
Wang, Ji-Yu ;
Ye, Meng ;
Zhuo, Xiao-Yun ;
Wang, Li-Tao ;
Chen, Hong ;
Zhang, Hua ;
Yang, Li .
LIFE SCIENCES, 2018, 205 :184-192
[9]
Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture [J].
Cortizo, AM ;
Sedlinsky, C ;
McCarthy, AD ;
Blanco, A ;
Schurman, L .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 536 (1-2) :38-46
[10]
L-ergothioneine and its combination with metformin attenuates renal dysfunction in type-2 diabetic rat model by activating Nrf2 antioxidant pathway [J].
Dare, Ayobami ;
Channa, Mahendra L. ;
Nadar, Anand .
BIOMEDICINE & PHARMACOTHERAPY, 2021, 141